Swiss stocks - Factors to watch on Sept 22
22/09/2016 06:11
ZURICH, Sept 22 (Reuters) - The following are some of the
main factors expected to affect Swiss stocks on Thursday:
SWISS-EU
Legislation giving locals hiring preference, a compromise
aimed at preserving Switzerland's economic treaties with the
European Union while still easing pressure on the job market
from foreign workers, cleared a first hurdle in Swiss parliament
on Wednesday.
For more, click on urn:newsml:reuters.com:*:nL8N1BX4CB
GATEGROUP GATE.S
The European Union (EU) regulators have greenlit the
acquisition of Swiss Gategroup by Chinese conglomerate HNA
Group, the EU said on Wednesday.
For more, click on GATE.S
BANKS
UBS UBSG.S and Credit Suisse CSGN.S are among the banks
which have set up offshore accounts for customers in the
Bahamas, Swiss newspaper Tages-Anzeiger reported. The two banks
have set up around 9,500 companies each in the tax free country
over the last 25 years, according to information revealed in a
data leak.
COMPANY STATEMENTS CPR-CH
* SGS SGSN.S said it acquired the assets and license of
John R. McCrea Agency, Inc. (McCrea), an official designated
inspection agency licensed by the US Department of Agriculture.
It expects it to generate annual revenues of approximately USD
0.5 million. SGSN.S
* Nestle NESN.S to launch global premium chocolate brands
range in India, the Economic Times reported. NESN.S
* Groupe Minoteries SA GMI.S said it had a net profit of
2.3 million Swiss francs in the first half of 2016. GMI.S
* Zueblin Immobilien Holding ZUBN.S said its CFO and COO
Thomas Wapp leaves the company at the end of March 2017 in order
to join Allreal Group ALLN.S as CFO. The company will inform
on his successor in due time. ZUBN.S ALLN.S
* Relief Therapeutics RLFB.S reported a first half loss of
4.62 million francs, from a loss 3.48 million francs a year
earlier. RLFB.S
* Newron Pharmaceuticals NWRN.S , a biopharmaceutical
company focused on the development of novel therapies for
patients with diseases of the central nervous system and pain,
said it has re-submitted the New Drug Application (NDA) for
Xadago (safinamide), a treatment for Parkinson's disease, to the
US Food and Drug Administration. NWRN.S
* Huber + Suhner HUBN.S said it struck a strategic
alliance with Germany's Weidmueller to be able to supply rail
industry customers with complete, 100 percent tested solutions
for the connection and transmission of power, signals and data.
HUBN.S
ECONOMY M-CH
(Reporting by Zurich newsroom)
((+41 58 306 7336)(zurich.newsroom@thomsonreuters.com))
((For Top News in a multimedia Web format on Eikon visit:
https://emea1.views.cp.extranet.thomsonreuters.biz/Explorer/NEWSxTOPNEWS.aspx?group=SP_GROUP_001&page=SP_PAGE_001&pageName=FrontPage
FOR RELATED PRICES, NEWS AND OTHER TOPICS, DOUBLE-CLICK ON:
Daily Swiss stock market report in German................ .SDE
All SMI constituent stocks............................ 0#.SSMI
News on major Swiss stock price moves.................. CH-HOT
FTSE Eurotop 300 index................................ .FTEU3
DJ STOXX index........................................ .STOXX
Top 10 STOXX sectors............................. .PGL.STOXXS
Top 10 EUROSTOXX sectors........................ .PGL.STOXXES
Top 10 Eurotop 300 sectors....................... .PGL.FTEU3S
Top 25 European pct gainers... .PG.PEUR , losers... .PL.PEUR
Swiss mid-cap index .SSMI SMI futures 0#SMI:
Swiss all-share index .SSHI Market statistics CH/STATS1
Swiss market digest .AD.S Sector overview CH/SECTOR1
All Swiss news CH Swiss research news CH-RCH
All equity news E
INTERNET ADDRESSES:
Swiss Exchange www.swx.ch/
Eurex www.eurexchange.com
STOXX Ltd www.stoxx.com
SPEED GUIDES: VX/EQUITY EQUITY EQUITY/NEWS1 EUR/EQUITY
SWITZERLAND REUTERS ))
Keywords: MARKETS SWISS STOCKS/